Idecabtagene vicleucel
As of the edition of 20 October 2026, Idecabtagene vicleucel is a gene: marketed, first approved in 2021 (US); acts on TNFRSF17; US protection ends in 2033.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Gene
- Brand name
- Abecma
- First approved
- 3 March 2021 (US)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Bristol Myers Squibb; 2 holders in all
- Registered trials
- 15, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Infections; Nutrition and metabolism
US protection
US protection ends in 2033.
US protection ends in 2033, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Bristol Myers Squibb. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Idecabtagene vicleucel.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF17 | Tumor necrosis factor receptor superfamily member 17 | Q02223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 0 | 4 | 0 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 5 | 3 | 2 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Originator, Applicant and Lead sponsor of trials | 2021 to now |